Solutions

Online Inquiry

Global Services. (Creative Biolabs Authorized)

Combination Immunotherapy Development Services

Online Inquiry

Background Introduction: The Future of Cancer Treatment

The immunotherapy revolution has rewritten the rules of cancer treatment. Now, researchers are pushing further by combining complementary approaches - creating multi-pronged attacks that outmaneuver tumors' defenses.

How these combos work:

Checkpoint inhibitors release the immune system's brakes
Adoptive cell therapies add reinforcements of engineered immune soldiers
CAR-T cells provide precision-guided tumor targeting

At Creative Biolabs, we offer Combination Immunotherapy Development Services, bringing together cutting-edge techniques and expertise to guide the development of effective combination therapies tailored to individual patient needs.

Fig.1 Schematic diagram. (OA Literature) Fig.1 Schematic diagram of adoptive T-cell therapy.¹

Main Service Offerings: Comprehensive Development Pathways

Our Combination Immunotherapy Development Services encompass several specialized offerings to optimize and implement combination therapies. These include:

Metabolic Immunoengineering Based Adoptive Cell Therapy (ACT) Optimization Service

Adoptive Cell Therapy (ACT) involves the infusion of immune cells that have been engineered or expanded ex vivo to target cancer cells. With our Metabolic Immunoengineering-Based ACT Optimization Service, we focus on enhancing the metabolic properties of these cells to boost their anti-tumor efficacy.

Service Overview: We employ metabolic reprogramming strategies to optimize the energy utilization and functionality of T cells, ensuring that they thrive during and after the infusion process. By manipulating metabolic pathways, we enhance the persistence, proliferation, and cytotoxic activity of these cells against cancer targets.

Metabolic Immunoengineering Based CAR-T Cell Optimization Service

CAR-T therapy has revolutionized cancer treatment - but we're taking it further. Our metabolic optimization service transforms these living drugs into more powerful, persistent tumor fighters. How We Upgrade Your CAR-T Cells:

Metabolic Reprogramming
Smart Expansion Protocols
Battle-Ready Enhancements

Metabolism and Immune Checkpoint Inhibitor Combination Therapy Development Service

Checkpoint inhibitors, which unleash T cells from regulatory constraints, have revolutionized cancer treatment. Our Metabolism and Immune Checkpoint Inhibitor Combination Therapy Development Service focuses on developing strategies that synergize metabolic interventions with checkpoint inhibitors.

Service Overview: By understanding the metabolic needs of tumors and immune cells, we develop protocols that combine metabolic modulation with checkpoint blockade therapies. This dual approach aims to enhance T cell activity, promote tumor regression, and improve responses to treatment.

Why Choose Creative Biolabs

Fig.2 Advantages. (Creative Biolabs Original)

Frequently Asked Questions

Q1: Can I test different metabolic targets in combination with my CAR-T construct?

A1: Yes. We provide a library of modulators and genetic tools to help identify the most effective metabolic pathways for your specific CAR-T cell.

Q2: Which tumor models can we use for testing in live animals?

A2: Pick the model that best matches your research needs:

Humanized mice for studying human immune-tumor interactions
Syngeneic models for intact murine immune systems
Orthotopic implants that mimic real tumor microenvironments

Our team will help you select the right setup based on your cell type and cancer targets.

Q3: How do you measure whether drug combinations work better together?

A3: We go beyond simple additive effects by:

Mapping drug interactions with precision dose grids
Tracking 20+ cytokines to monitor immune activity
Running parallel functional tests on both immune cells and tumors

This multi-angle approach catches synergistic effects others might miss.

Partnering with Creative Biolabs: Your Strategic Ally in Immunotherapy Development

When you work with our team, you're not just getting another CRO - you're gaining a strategic ally with:

25 years' deep dive into immunotherapy mechanisms
Unique metabolic + immune system cross-expertise
End-to-end capabilities - from initial concept to preclinical proof

We've helped 50+ biotechs crack their toughest combination therapy challenges by:

Designing smarter drug pairings based on tumor metabolism
Avoiding common synergy pitfalls with our proprietary screening
Validating results in clinically relevant models

The Creative Biolabs Difference:

Instead of cookie-cutter solutions, we build custom development roadmaps that account for:

Tumor microenvironment dynamics

Immune cell metabolic demands

Therapeutic sequencing effects

Let's engineer your breakthrough:

Reference

Barbari, Cody et al. "Immunotherapies and Combination Strategies for Immuno-Oncology." International journal of molecular sciences vol. 21,14 5009. Distributed under Open Access License CC BY 4.0, without modification.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.